These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2524410)

  • 1. [Studies on the pressor mechanism of 19-hydroxyandrostenedione].
    Honda M; Minato M; Takayama R; Nagashima Y; Watanabe M; Izumi Y; Fukuda N; Soma M; Shiratsuchi T; Watanabe Y
    Nihon Naibunpi Gakkai Zasshi; 1989 Jan; 65(1):18-31. PubMed ID: 2524410
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate (DOCA)-salt hypertension].
    Minato M; Honda M; Hatano M
    Nihon Naibunpi Gakkai Zasshi; 1990 Jan; 66(1):29-41. PubMed ID: 2307256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 19-Hydroxyandrostenedione amplifies the hypertensive action of mineralocorticoids in rats.
    Sekihara H; Yazaki Y; Kojima T
    J Endocrinol; 1993 Jul; 138(1):31-40. PubMed ID: 7852890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reevaluation of the mineralocorticoid and hypertensinogenic potential of 19-hydroxyandrostenedione.
    Gomez-Sanchez EP; Gomez-Sanchez CE
    Endocrinology; 1986 Jun; 118(6):2582-7. PubMed ID: 3698922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 19-hydroxyandrostenedione as a new hypertensinogenic agent.
    Sekihara H
    J Steroid Biochem; 1982 Feb; 16(2):329-31. PubMed ID: 7043093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A comparative study of C19 steroid-induced hypertension and deoxycorticosterone acetate (DOCA)-salt hypertension].
    Manabe R; Honda M; Hatano M
    Nihon Naibunpi Gakkai Zasshi; 1984 Nov; 60(11):1328-37. PubMed ID: 6526083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased release of atrial natriuretic polypeptides in rats with DOCA-salt hypertension.
    Sugimoto T; Ishii M; Hirata Y; Matsuoka H; Sugimoto T; Miyata A; Toshimori T; Masuda H; Kangawa K; Matsuo H
    Life Sci; 1986 Apr; 38(15):1351-8. PubMed ID: 2937987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preventive effect of angiotensin I on weight reduction in the adrenal glands of DOCA/salt hypertensive rats.
    Watanabe M; Honda M; Soma M; Minato M; Fukuda N; Watanabe Y; Izumi Y; Hatano M
    Endocrinol Jpn; 1990 Aug; 37(4):521-8. PubMed ID: 2083530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 19-Hydroxyandrostenedione: evidence for a new class of sodium-retaining and hypertensinogenic steroids.
    Sekihara H
    Endocrinology; 1983 Sep; 113(3):1141-8. PubMed ID: 6347666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 19-Hydroxyandrostenedione: a potent hypertensinogenic steroid in man.
    Sekihara H
    J Steroid Biochem; 1983 Jul; 19(1A):353-8. PubMed ID: 6310235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of Na+-K+ ATPase activity on blood pressure regulation and sodium metabolism in DOCA-treated rats].
    Shigetomi S; Tosaki H; Ueno S; Kohno H; Mori K; Katoh K; Tanaka K; Haga H; Kin S; Matsunaga A
    Nihon Naibunpi Gakkai Zasshi; 1989 Oct; 65(10):1198-207. PubMed ID: 2556303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DOCA administration and atrial natriuretic factor in dogs with chronic heart failure.
    Villarreal D; Freeman RH; Brands MW
    Am J Physiol; 1989 Sep; 257(3 Pt 2):H739-45. PubMed ID: 2528918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 6 beta-Hydroxyandrostenedione: evidence for a new hypertensinogenic agent.
    Sekihara H
    Clin Exp Hypertens A; 1983; 5(1):1-9. PubMed ID: 6339119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma atrial natriuretic peptide in DOCA-NaCl-treated rats.
    Tikkanen T; Tikkanen I; Fyhrquist F
    Acta Physiol Scand; 1987 Feb; 129(2):151-5. PubMed ID: 2953170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low plasma 19-hydroxyandrostenedione levels in patients with aldosterone-producing adenoma.
    Morita H; Mune T; Yasuda K; Yamakita N; Miyazaki S; Miura K
    Endocr J; 1993 Feb; 40(1):89-97. PubMed ID: 7951501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II and atrial natriuretic factor-binding sites in various tissues in hypertension: comparative receptor localization and changes in different hypertension models in the rat.
    Wilson SK; Lynch DR; Ladenson PW
    Endocrinology; 1989 Jun; 124(6):2799-808. PubMed ID: 2542000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of 19-nor-deoxycorticosterone on blood pressure, saline consumption, and serum electrolytes, corticosterone, and renin activity.
    Hall CE; Gomez-Sanchez CE; Holland OB; Nasseth D
    Endocrinology; 1979 Sep; 105(3):600-4. PubMed ID: 157270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phasic plasma atrial natriuretic polypeptide changes in DOCA-salt hypertensive rats.
    Sato Y; Ito Y; Ando K; Ogata E; Fujita T
    Jpn Heart J; 1990 Sep; 31(5):703-11. PubMed ID: 2148777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of 5 alpha-dihydrocortisol on the blood pressure of rats treated with deoxycorticosterone acetate and salt.
    Mikami H; Nugent CA; Ogihara T; Naka T; Iwanaga K; Kumahara Y
    Endocrinol Jpn; 1980 Dec; 27(6):769-73. PubMed ID: 7021137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of brain mineralocorticoid receptor blockade on blood pressure and renal functions in DOCA-salt hypertension.
    Rahmouni K; Sibug RM; De Kloet ER; Barthelmebs M; Grima M; Imbs JL; De Jong W
    Eur J Pharmacol; 2002 Feb; 436(3):207-16. PubMed ID: 11858800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.